Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
212 hedge funds and large institutions have $4.55B invested in Apellis Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 24 closing their positions.
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
19% more capital invested
Capital invested by funds: $3.83B → $4.55B (+$721M)
16% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 63
14% more funds holding
Funds holding: 186 → 212 (+26)
2.12% more ownership
Funds ownership: 84.36% → 86.48% (+2.1%)
1% less call options, than puts
Call options by funds: $82.1M | Put options by funds: $82.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$114M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$82.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$57.6M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$50.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$40.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$85.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.2M |
| 3 |
DM
Deerfield Management
New York
|
-$16.2M |
| 4 |
TLP
Tri Locum Partners
New York
|
-$15M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$14.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$445K | -9,406 | Closed |
|
|
ACM
227
AlphaCrest Capital Management
New York
| – | -$405K | -8,556 | Closed |
|
|
AC
228
Allstate Corporation
Northbrook,
Illinois
| – | -$316K | -6,694 | Closed |
|
|
CWG
229
Crown Wealth Group
Charlotte,
North Carolina
| – | -$238K | -5,040 | Closed |
|
|
LSA
230
Leonteq Securities AG
Zurich,
Switzerland
| – | -$105K | -2,223 | Closed |
|
|
EVM
231
Eaton Vance Management
Boston,
Massachusetts
| – | -$96K | -2,025 | Closed |
|
|
CA
232
CoreCap Advisors
Southfield,
Michigan
| – | -$14K | -300 | Closed |
|
|
AF
233
Allworth Financial
Folsom,
California
| – | -$8.83K | -200 | -98% |
|
|
SGAM
234
Smith Group Asset Management
Dallas,
Texas
| – | -$4K | -80 | Closed |
|
|
CAL
235
Capital Analysts LLC
Fort Washington,
Pennsylvania
| – | -$3K | -57 | Closed |
|
APLS Hedge Fund Activity: Q1 2022 in Review
212 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2022, worth a combined $4.55B — up 19% from $3.83B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new APLS positions and 24 closed out — a net gain of 29 holders — while 73 added to existing stakes and 63 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $114M. The largest seller was RTW Investments, cutting an estimated $85.6M.
- 212 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2022, up from 186 in Q4 2021.
- Funds reported $4.55B of Apellis Pharmaceuticals stock for Q1 2022, up 19% quarter-over-quarter.
- 53 funds opened new Apellis Pharmaceuticals positions in Q1 2022 and 24 closed out, a net change of +29 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2022 was T. Rowe Price Associates, an estimated $114M added.
- The largest Apellis Pharmaceuticals seller in Q1 2022 was RTW Investments, an estimated $85.6M sold.
Based on aggregated 13F filings for Q1 2022.